First Trust Advisors LP Immuno Gen, Inc. Transaction History

First Trust Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$12.46 - $29.95 $3.83 Million - $9.21 Million	307,539 New	307,539 $9.12 Million
Q4 2021 Feb 08, 2022	SELL	$4.75 - $7.5 $370,462 - $584,940	-77,992 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$5.02 - $6.59 $2.55 Million - $3.35 Million	-508,123 Reduced 86.69%	77,992 $442,000
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $3.39 Million - $5.04 Million	586,115 New	586,115 $3.86 Million
Q4 2018 Feb 07, 2019	SELL	$3.94 - $9.7 $1.12 Million - $2.77 Million	-285,406 Closed	0 $0
Q3 2018 Oct 25, 2018	SELL	$8.6 - $11.26 $723,449 - $947,213	-84,122 Reduced 22.76%	285,406 $2.7 Million
Q2 2018 Aug 02, 2018	BUY	$9.52 - $12.15 $3.52 Million - $4.49 Million	369,528 New	369,528 $3.6 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.